- Phase 2 AIRLEAF trial results indicate that BI 1291583, a cathepsin C inhibitor, reduces the risk of pulmonary exacerbations in adults with bronchiectasis. - The study showed a dose-dependent benefit of BI 1291583 compared to placebo in time to first pulmonary exacerbation over 48 weeks. - A 29% decreased risk of initial pulmonary exacerbation was observed with the 5 mg dose of BI 1291583 compared to placebo, though statistical significance was not reached. - A phase 3 trial (AIRTIVITY) is planned for 2025 to further evaluate BI 1291583 in bronchiectasis patients.

Sep 25, 2024

返回机构列表

Boehringer Ingelheim International GmbH

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（358）

A study in healthy people to compare how 2 different formulations of vicadrostat / empagliflozin tablets are taken up in the body

A study in healthy men to test whether carbamazepine influences the amount of verducatib in the blood

A study in healthy people to test how Zongertinib is taken up in the body when given as tablets made by two different manufacturers with or without food

A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood

A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity

A study to test how well different and multiple doses of BI 3034701 are tolerated in people living with overweight or obesity

A study in healthy people to measure how different doses of verducatib affect the heart

A study in healthy people to compare two tablet formulations of pramipexole

药物批准

按机构分类的批准

近期批准

资讯

Cathepsin C Inhibitor BI 1291583 Shows Promise in Reducing Bronchiectasis Exacerbations